CSPC Pharmaceutical Group ( (HK:1093) ) has provided an update.
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, released its 2024 annual financial report, showing a significant decline in revenue and net profit compared to the previous year. The report highlights a 21.98% decrease in revenue and an 87.63% drop in net profit attributable to shareholders, indicating financial challenges that may impact the company’s market positioning and stakeholder confidence.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated company operating in the pharmaceutical industry. It focuses on the development, manufacturing, and marketing of pharmaceutical products, with a significant presence in the Chinese market.
YTD Price Performance: 9.49%
Average Trading Volume: 6,363
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $7.4B
Learn more about 1093 stock on TipRanks’ Stock Analysis page.